Lamotrigine prophylaxis is associated with reduced aura frequency in patients with burdensome migraine aura: a retrospective observational study.

Migraine aura affects about one-third of migraine sufferers. For some, this condition is very disabling. Effective treatments are often lacking for these patients. This study looked at lamotrigine (LTG) as a treatment option. It involved 81 patients from a neurology clinic in Lund, Sweden. These patients experienced frequent or severe migraine aura. Researchers wanted to see if LTG could help reduce aura days. They measured the number of aura days before and after starting LTG. Before treatment, patients had an average of 6.9 aura days per month. After starting LTG, this decreased to 1.4 days per month. This was a significant reduction of 79.7%. The overall response rate was 85.2%, meaning most patients improved. Some patients experienced side effects, with skin changes being the most common. Overall, LTG appears to be a promising option for managing migraine aura. Clinical relevance: This study shows that lamotrigine can significantly reduce migraine aura frequency, offering hope for better management options for patients suffering from this debilitating condition.